|
Price: $0.2740
$-0.03 
-10.164%
|
| Day's High:
| $0.32
| Week Perf:
| -16.97 %
|
| Day's Low: |
$ 0.27 |
30 Day Perf: |
-15.69 % |
| Volume (M): |
407 |
52 Wk High: |
$ 3.49 |
| Volume (M$): |
$ 112 |
52 Wk Avg: |
$1.17 |
| Open: |
$0.32 |
52 Wk Low: |
$0.27 |
|
|
| Market Capitalization (Millions $) |
42 |
| Shares
Outstanding (Millions) |
154 |
| Employees |
51 |
| Revenues (TTM) (Millions $) |
199 |
| Net Income (TTM) (Millions $) |
-257 |
| Cash Flow (TTM) (Millions $) |
-194 |
| Capital Exp. (TTM) (Millions $) |
28 |
Cue Health Inc
Cue Health Inc.
is a healthcare technology company that provides a range of diagnostic products and services to individuals and healthcare providers.
The company's primary focus is on the development and commercialization of portable, easy-to-use diagnostic devices that allow individuals to monitor their health at home or in other settings.
Cue Health's flagship product is a compact, battery-powered device called the Cue Health Monitoring System, which uses a small cartridge to conduct a range of diagnostic tests, from measuring biomarkers such as vitamin D levels to detecting influenza and COVID-19.
The system is designed to provide accurate results within minutes and can be connected to a mobile app that allows individuals to track their health over time.
The company also offers a COVID-19 testing service in partnership with healthcare providers and employers, using the Cue Health Monitoring System to conduct rapid tests in a variety of settings, from schools and sporting events to airports and workplaces.
The service aims to help identify and isolate individuals who may be infected with the virus, as well as to provide employers with insights into the health of their workforce.
Cue Health was founded in 2010 by a team of scientists, engineers, and entrepreneurs with the goal of making healthcare more accessible and convenient for individuals.
The company is headquartered in San Diego, California, and has raised over $230 million in funding from investors including Johnson & Johnson and Decheng Capital.
Company Address: 4980 Carroll Canyon Rd. San Diego 92121 CA
Company Phone Number: 412-8151 Stock Exchange / Ticker: NASDAQ HLTH
| HLTH is expected to report next financial results on March 15, 2024. |
|
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
|
Cytek Biosciences Inc
Cytek Biosciences Inc (CTKB) has shown impressive growth in its stock value, gaining 12.39% over the past five trading days. Additionally, despite a challenging year, the company's stock has seen a significant increase of 66.55% compared to the previous year. Furthermore, Cytek Biosciences Inc's stock currently trades 28.9% above its 52-week low. Analyzing these financial results, it becomes evident that the company has managed to battle industry headwinds and achieve notable progress. However, it is crucial to consider the company's recent fiscal performance and other factors that may impact the company's future outlook.
Fiscal Performance:
For the fiscal period ending September 30, 2023, Cytek Biosciences Inc has recorded a shortfall per share of -$0.05, compared to a positive $0.01 per share a year earlier. This represents a decline from the preceding reporting season's shortfall of -$0.03 per share. Although the company has experienced a widening shortfall, it is important to note that revenue has increased significantly.
|
|
Talis Biomedical Corporation
The latest financial results reported by Talis Biomedical Corporation for the period ending September 30, 2023, paint a bleak picture. With a significant decline in revenue and expanding net deficits, the company has announced its intention to explore strategic alternatives to maximize shareholder value. This article will delve into the impact these results may have on the company's future prospects.
Dismal Revenue and Widening Deficit:
Talis Biomedical Corporation witnessed a staggering 82.412% decline in revenue compared to the same reporting period last year, earning only $0.14 million. This follows a 75.904% revenue drop from the previous reporting period, where the company generated $0.58 million. These figures indicate a concerning trend of declining sales.
|
|
Singular Genomics Systems Inc
The Laboratory Analytical Instruments company, Singular Genomics Systems Inc, reported limited revenue of only $0.462 million in the third quarter of 2023. Moreover, the company experienced a net loss of an alarming $-22.360 million in the same quarter, a significant deterioration compared to the previous year's deficit of $-23.790 million. Furthermore, inventories have declined to $13.4 million, indicating potential weakening future demand. These factors, coupled with other concerning indicators, suggest a bearish outlook for Singular Genomics Systems Inc.
Declining Inventories Reflect Lower Demand:
A critical aspect to assess a company's growth prospects lies in its inventory levels, which provide insight into future demand. Singular Genomics Systems Inc witnessed a decline in inventories to $13.4 million in the third quarter, compared to the previous quarter as well as the same period a year before. This reduction raises concerns about weakening demand and potential challenges the company may face in generating future revenue.
|
|
Illumina Inc
Illumina Inc, a Laboratory Analytical Instruments company, experienced a challenging third quarter in 2023, reporting a loss of $-4.77 per share. This marked an improvement from the previous year, where the loss per share was significantly higher at $-24.26.
Interestingly, while most companies in the Laboratory Analytical Instruments sector saw a decline in revenue, Illumina Inc managed to achieve a slight growth of 0.359%. The company's revenue reached $1.12 billion during the quarter, compared to $1.12 billion in the same period the previous year. However, there was a sequential decrease in revenue of -4.847% from $1.18 billion.
|
|
Astrotech Corp
Astrotech Corp is a company operating in the Laboratory Analytical Instruments sector that has experienced strong revenue growth in the first quarter of the 2024 earnings season. Despite this positive revenue increase of 1018.421% year on year to $0.43 million, the company also saw a significant increase in its deficit per share at $-1.79.
In comparison to the previous quarter, there was an increase in the deficit per share from $-1.44 and a revenue increase of 2.657% from $0.41 million. This suggests that Astrotech Corp is performing well relative to other companies in the same sector, as many have been affected by receding transactions and declining top-line figures.
|
| Per Share |
Current |
| Earnings (TTM) |
-1.6 $ |
| Revenues (TTM) |
1.29 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.73 $
|
| Book Value |
2.53 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.6 $
|
| Revenues (TTM) |
1.29 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.73 $
|
| Book Value |
2.53 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
